Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis"
Antimicrob Agents Chemother
.
2017 Aug 24;61(9):e01524-17.
doi: 10.1128/AAC.01524-17.
Print 2017 Sep.
Authors
C A Peloquin
1
,
G E Velásquez
2
3
,
L Lecca
3
4
,
R I Calderón
4
,
J Coit
2
,
M Milstein
2
,
E Osso
2
,
J Jimenez
4
,
K Tintaya
4
,
E Sanchez Garavito
5
,
D Vargas Vasquez
6
,
C D Mitnick
3
7
,
G Davies
8
Affiliations
1
University of Florida College of Pharmacy and Emerging Pathogens Institute, Gainesville, Florida, USA.
2
Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
3
Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
4
Socios En Salud, Lima, Peru.
5
Hospital Nacional Sergio Bernales, Lima, Peru.
6
Hospital Nacional Hipólito Unanue, Lima, Peru.
7
Partners In Health, Boston, Massachusetts, USA.
8
Institutes of Infection and Global Health and Translational Medicine, University of Liverpool, Liverpool, United Kingdom.
PMID:
28839086
PMCID:
PMC5571311
DOI:
10.1128/AAC.01524-17
No abstract available
Publication types
Published Erratum
Grants and funding
L30 AI120170/AI/NIAID NIH HHS/United States
U01 AI091429/AI/NIAID NIH HHS/United States